Display options
Cite
Yuan Q, Jiang YW, Ma TT, et al. Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats. J Inflamm (Lond). 2014;11(1):40doi: 10.1186/s12950-014-0040-5.
Yuan, Q., Jiang, Y. W., Ma, T. T., Fang, Q. H., & Pan, L. (2014). Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats. Journal of inflammation (London, England), 11(1), 40. https://doi.org/10.1186/s12950-014-0040-5
Yuan, Qing, et al. "Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats." Journal of inflammation (London, England) vol. 11,1 (2014): 40. doi: https://doi.org/10.1186/s12950-014-0040-5
Yuan Q, Jiang YW, Ma TT, Fang QH, Pan L. Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats. J Inflamm (Lond). 2014 Dec 05;11(1):40. doi: 10.1186/s12950-014-0040-5. eCollection 2014. PMID: 25530718; PMCID: PMC4272525.
Copy Download .nbib Format: NLM
Share it on

J Inflamm (Lond). 2014 Dec 05;11(1):40. doi: 10.1186/s12950-014-0040-5. eCollection 2014.

Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats.

Journal of inflammation (London, England)

Qing Yuan, Yan-Wen Jiang, Ting-Ting Ma, Qiu-Hong Fang, Lei Pan

Affiliations

  1. Intensive Care Unit of Geriatrics, Beijing Shijitan Hospital Affiliated to Capital Medicine University, No.10 Tieyi Road, Beijing, 100038 Haidian District People's Republic of China.
  2. Department of Pulmonary and Critical Care Medicine, Beijing Shijitan Hospital Affiliated to Capital Medicine University, No.10 Tieyi Road, Beijing, 100038 Haidian District People's Republic of China.
  3. Department of Geriatrics, Beijing Shijitan Hospital Affiliated to Capital Medicine University, No.10 Tieyi Road, Beijing, 100038 Haidian District People's Republic of China.

PMID: 25530718 PMCID: PMC4272525 DOI: 10.1186/s12950-014-0040-5

Abstract

BACKGROUND: Sepsis causes neutrophil sequestration in the lung which leads to acute lung injury (ALI). Radix Ginseng (RG), a traditional herb used as herbal remedy in eastern Asia for thousands of years, which has been traditionally used in China to improve blood circulation and ameliorate pathological hemostasis. This study investigated whether Ginsenoside Rb1, the main components of RG, can attenuate ALI induced by LPS.

METHODS: In vivo, 30 male Wistar rats were divided into three groups (n = 10 each groups) on the basis of the reagent used, which were subjected to LPS injection with or without Ginsenoside Rb1 (5 mg/kg) treatments to induce ALI model. Lung injury was assessed by pulmonary histology, lung wet-weight to dry-weight (W/D) ratio, the number of myeloperoxidase (MPO) positive cells, immunohistochemical analysis of intercellular adhesion molecule-1 (ICAM-1), gene expression of ICAM-1, ultrastructure changes of pulmonary microvasculature, concentration of inflammatory markers and in plasma. In vitro, pulmonary microvascular endothelial cells (PMVECs) were stimulated with LPS in the presence and absence of Ginsenoside Rb1 (50 mM), nuclear factor-κB (NF-κB) p65 was measured by immunocytochemistry staining and western blotting.

RESULTS: Infusion of LPS induced lung injury, in vivo, as demonstrated by pulmonary edema with infiltration of neutrophils and hemorrhage, the increase in lung W/D ratio, the number of MPO positive cells, the level of inflammatory markers such as TNF-α, MCP-1 and IL-8, enhanced expression of ICAM-1 and ICAM-1 gene. Moreover, resulted in the changes of intercellular junctions in the endothelial cells of pulmonary microvasculature. In vitro, the significant increased release of NF-κB p65 and its subsequent translocation into the nucleus in PMVECs were observed. In contrast, Ginsenoside Rb1 treatment significantly ameliorated the LPS-induced lung injury, as judged by the marked improvement in all these indices.

CONCLUSIONS: These results indicate that Ginsenoside Rb1 attenuated LPS-induced lung injury through an inhibition of the inflammatory signaling pathway, besides the direct inhibitory effect on proinflammatory molecules.

Keywords: Acute lung injury; Ginsenoside Rb1; ICAM-1; LPS; MPO; NF-κB P65

References

  1. Molecules. 2013 Jan 17;18(1):1214-26 - PubMed
  2. J Immunol. 2004 Nov 15;173(10):6376-83 - PubMed
  3. Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381(6):483-93 - PubMed
  4. Yonsei Med J. 1991 Dec;32(4):303-14 - PubMed
  5. Mol Biol Rep. 2011 Aug;38(6):3615-22 - PubMed
  6. Expert Rev Clin Immunol. 2009 Jan 1;5(1):63-75 - PubMed
  7. J Immunol. 2012 Dec 1;189(11):5402-10 - PubMed
  8. Shock. 2009 Sep;32(3):310-6 - PubMed
  9. Shock. 2012 Aug;38(3):320-7 - PubMed
  10. Atherosclerosis. 2006 Apr;185(2):331-9 - PubMed
  11. J Inflamm (Lond). 2011 May 02;8:10 - PubMed
  12. Am J Physiol Renal Physiol. 2006 Nov;291(5):F1090-5 - PubMed
  13. PLoS One. 2013 May 09;8(5):e63845 - PubMed
  14. J Immunol. 2004 Apr 1;172(7):4535-44 - PubMed
  15. Pharmacol Res. 2009 Oct;60(4):296-302 - PubMed
  16. Exp Biol Med (Maywood). 2006 Jun;231(6):985-91 - PubMed
  17. Thromb Haemost. 2009 Apr;101(4):724-33 - PubMed
  18. Mol Vis. 2007 Jul 23;13:1259-73 - PubMed
  19. Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L807-15 - PubMed
  20. J Cell Physiol. 1998 Jul;176(1):76-84 - PubMed
  21. Circ Res. 2008 Aug 15;103(4):352-9 - PubMed
  22. Ann Cardiol Angeiol (Paris). 1986 Oct 15;35(7 Pt 2):439-46 - PubMed
  23. Biochem Biophys Res Commun. 2011 Jul 8;410(3):494-500 - PubMed
  24. Arch Cardiovasc Dis. 2013 Mar;106(3):169-77 - PubMed
  25. Biomed Environ Sci. 2014 Apr;27(4):300-3 - PubMed
  26. J Physiol Pharmacol. 2005 Sep;56 Suppl 4:47-64 - PubMed
  27. Pancreas. 2010 Oct;39(7):1057-63 - PubMed
  28. Inflammation. 2012 Jun;35(3):1161-8 - PubMed
  29. Dev Biol. 1989 Mar;132(1):230-40 - PubMed
  30. Proc Natl Acad Sci U S A. 2012 Aug 28;109 (35):14146-51 - PubMed
  31. Shock. 2012 May;37(5):548-55 - PubMed
  32. Shock. 2004 May;21(5):470-5 - PubMed
  33. Toxicol Appl Pharmacol. 2010 Oct 15;248(2):89-99 - PubMed
  34. Life Sci. 2007 Jul 19;81(6):509-18 - PubMed

Publication Types